XVIVO Perfusion: Strong growth and operational leverage - Redeye

XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations. The main growth driver is disposables, where Thoracic, XVIVO’s most prominent business unit, delivered 50% organic growth and improved disposables gross margins to 87%. XVIVO continues to invest in sustainable growth during 2025 ahead of substantial launch support.

Länk till analysen i sin helhet: https://www.redeye.se/research/1070322/xvivo-perfusion-strong-growth-and-operational-leverage?utm_source=finwire&utm_medium=RSS